BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main GoalZacks Investment Research • 05/15/26
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?Zacks Investment Research • 05/14/26
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight LossBenzinga • 05/13/26
Patients don't regain much weight switching from injections to Lilly's weight-loss pill, study findsReuters • 05/12/26
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsPRNewsWire • 05/12/26
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesPRNewsWire • 05/12/26
Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarityReuters • 05/11/26
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTABusiness Wire • 05/11/26
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label ExpansionsSeeking Alpha • 05/10/26
Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptakeReuters • 05/08/26
Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked OffInvestors Business Daily • 05/08/26